Statins tied to lower risk for postcolonoscopy CRC

  • Cheung KS & al.
  • Gut
  • 26 Feb 2019

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Among patients who had a colonoscopy, statin use was associated with a lower risk for diagnosis of colorectal cancer (CRC) in the following 3 years (PCCRC-3y).

Why this matters

  • The potential risk reduction could help guide clinical decision-making regarding statin prescription in patients at high risk for CRC and borderline cardiovascular risk.

Study design

  • Retrospective analysis of 187,897 patients in Hong Kong who underwent colonoscopy between 2005 and 2013.
  • Funding: None disclosed.

Key results

  • Propensity score matching between 17,662 statin users and 30,304 nonusers showed statin use was associated with a lower risk for PCCRC-3y (subdistribution HR [SHR], 0.72; 95% CI, 0.55-0.95; number needed to treat, 498).
  • Statin use was associated with:
    • Lower risk for proximal CRC (SHR, 0.50; 95% CI, 0.28-0.91), but not distal CRC (SHR, 0.80; 95% CI, 0.59-1.09).
    • A dose-dependent reduction in PCCRC-3y risk (SHR, 0.93; 95% CI, 0.87-0.99; for every 100 increase in cumulative defined daily dose; P=.023).
    • Lower PCCRC-3y risk in patients aged ≥60 years (SHR, 0.72; 95% CI, 0.56-0.92), women (SHR, 0.35; 95% CI, 0.22-0.58), nondiabetic patients (SHR, 0.59; 95% CI, 0.42-0.81), and patients with no history of polyps and/or polypectomy (SHR, 0.58; 95% CI, 0.41-0.83).

Limitations

  • Asian population.
  • Retrospective analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit